Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3Natalia Sergina, Mark M. Moasser, Jimmy A. Blair et al.|Nature|2007Cited by 991
Resiliency and Vulnerability in the HER2-HER3 Tumorigenic DriverDhara N. Amin, Mark M. Moasser, Natalia Sergina et al.|Science Translational Medicine|2010Cited by 185
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibitionNeil E. Torbett, David Stokoe, Kevan M. Shokat et al.|Biochemical Journal|2008Cited by 125
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique DomainAna Ruiz-Sáenz, Mark M. Moasser|Molecular Cancer Research|2021Cited by 14